MAPT and supranuclear palsy, progressive, 1: Further support for tau pathology as the neuropathological substrate of the parkinsonism observed in LRRK2 mutation carriers has come from the identification of progressive supranuclear palsy (PSP)-like tau inclusions observed in several cases [15–18].